Abstract
Despite advances in surgery and drug discovery, brain tumors remain fatal diseases. Early detection and diagnosis of brain tumors is of great importance for improving treatment outcomes. Magnetic resonance imaging (MRI) is a prominent, clinically-relevant imaging modality because of its excellent tissue contrast resolution, direct multiplanar imaging and increased sensitivity to edema. MRI utility is further enhanced with the use of magnetic iron oxide nanoparticles, which can function as both a contrast agent for imaging and as a drug delivery vehicle for treating brain cancer. In this review, the principles of various imaging modalities for brain tumors are discussed with focus on monocrystalline iron oxide nanoparticle (MION)-based MRI contrast agents. A summary is given on the mechanism of contrast effect, magnetophoretic mobility and magnetic retention, and strategies to enhance tumor selectivity, increase spatial resolution and reduce nonspecific uptake of MION.
Keywords: Brain tumors, imaging, MRI, iron oxide nanoparticles, targeting, iron oxide nanoparticles, drug discovery, magnetic iron oxide nanoparticles, treating brain cancer, oxide nanoparticle (MION)-based, Brain cancers, metastatic brain tumor, solid tumor cancer, glioblastoma multiforme (GBM)
Current Pharmaceutical Biotechnology
Title:Magnetic Nanoparticles for MRI of Brain Tumors
Volume: 13 Issue: 12
Author(s): Jianxin Wang, Yongzhuo Huang, Allan E. David, Beata Chertok, Lei Zhang, Faquan Yu and Victor C. Yang
Affiliation:
Keywords: Brain tumors, imaging, MRI, iron oxide nanoparticles, targeting, iron oxide nanoparticles, drug discovery, magnetic iron oxide nanoparticles, treating brain cancer, oxide nanoparticle (MION)-based, Brain cancers, metastatic brain tumor, solid tumor cancer, glioblastoma multiforme (GBM)
Abstract: Despite advances in surgery and drug discovery, brain tumors remain fatal diseases. Early detection and diagnosis of brain tumors is of great importance for improving treatment outcomes. Magnetic resonance imaging (MRI) is a prominent, clinically-relevant imaging modality because of its excellent tissue contrast resolution, direct multiplanar imaging and increased sensitivity to edema. MRI utility is further enhanced with the use of magnetic iron oxide nanoparticles, which can function as both a contrast agent for imaging and as a drug delivery vehicle for treating brain cancer. In this review, the principles of various imaging modalities for brain tumors are discussed with focus on monocrystalline iron oxide nanoparticle (MION)-based MRI contrast agents. A summary is given on the mechanism of contrast effect, magnetophoretic mobility and magnetic retention, and strategies to enhance tumor selectivity, increase spatial resolution and reduce nonspecific uptake of MION.
Export Options
About this article
Cite this article as:
Wang Jianxin, Huang Yongzhuo, E. David Allan, Chertok Beata, Zhang Lei, Yu Faquan and C. Yang Victor, Magnetic Nanoparticles for MRI of Brain Tumors, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341824
DOI https://dx.doi.org/10.2174/138920112803341824 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients
Current Pharmaceutical Design Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Factors Affecting the Metabolite Productions in Endophytes: Biotechnological Approaches for Production of Metabolites
Current Medicinal Chemistry Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets